Abstract:Objective: To investigate the potential of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in mitigating the adverse prognosis associated with central nervous system leukemia (CNSL) and to assess the significance of prophylactic intrathecal injection. Methods: A retrospective cohort analysis was conducted involving 30 patients with acute leukemia who had a history of CNSL who underwent allo-HSCT at Peking University People's Hospital between September 2012 and March 2018 (referred to as the CNSL-positive group). In addition, 90 patients with acute leukemia were selected from the same period who underwent allo-HSCT without a history of CNSL (referred to as the CNSL-negative group) and a rigorous 1∶3 matching was performed based on disease type, disease status, and transplantation type to form the control group. The prognosis between the two groups was compared using Kaplan-Meier analysis and the high-risk factors for CNSL relapse post-transplant were identified through Cox proportional-hazards model. Results: The median age of patients in the CNSL-negative group was significantly higher than that of patients in the CNSL-positive group (32 years vs. 24 years, P=0.014). No significant differences were observed in baseline data, including sex, disease type, disease status at transplantation, donor-recipient relationship, and human leukocyte antigen consistency between the two groups. The median follow-up time was 568 days (range: 21-1 852 days). The 4-year cumulative incidence of relapse (71.4%±20.9% vs. 29.3%±11.5%, P=0.005) and the cumulative incidence of CNSL post-transplant (33.6%±9.2% vs. 1.2%±1.2%, P<0.001) were significantly higher in the CNSL-positive group than in the CNSL-negative group. Furthermore, the 4-year leukemia-free survival rate in the CNSL-positive group was significantly lower than that in the CNSL-negative group (23.1%±17.0% vs. 71.5%±11.6%, P<0.001). However, no significant differences were observed in the 4-year cumulative transplant-related mortality and overall survival rates between the two groups (both P>0.05). Multivariate analysis revealed that a history of CNSL before transplantation (HR=25.050, 95%CI 3.072-204.300, P=0.003) was identified as high-risk factors for CNSL relapse post-transplant. Conversely, haploidentical transplantation was associated with a reduced risk of CNSL relapse post-transplant (HR=0.260, 95%CI 0.073-0.900, P=0.034). Within the CNSL-positive group, seven patients received prophylactic intrathecal therapy after transplantation, and their CNSL relapse rate was significantly lower than that of the 23 patients who did not receive intrathecal therapy after transplantation (0/7 vs. 9/23, P=0.048). Conclusions: Patients with a history of CNSL have a higher risk of relapse and experience poorer leukemia-free survival following transplantation. The use of prophylactic intrathecal injection shows promise in mitigating CNSL relapse rates, although further validation through prospective studies is necessary to substantiate these observations.

Neurological Complications Following Allogeneic Haematopoietic Stem Cell Transplantation

Clinical Characteristics and Prognostic Factors of Nephrotic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Clinical analysis of central nervous system complications afterallogeneic hematopoietic stem cell transplantation

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of Incidence, Risk Factors and Survival

Analysis of the Infectious Complications Following Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Intracranial Hemorrhage and Mortality in 1461 Patients after Allogeneic Hematopoietic Stem Cell Transplantation for 6-Year Follow-Up: Study of 44 Cases

Clinical study of the nervous system complications after hematopoietic stem cell transplantation

Reversible posterior leukoencephalopathy syndrome caused by allogeneic hematopoietic stem cell transplantation

Clinical Characteristics and Risk Factors of Intracranial Hemorrhage in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation.

Curative effect analysis of allogeneic hematopoietic stem cell transplantation for 150 patients with hematological malignancies

Central nervous system complications after hematopoietic stem cell transplantation

Epileptic Seizures in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation: a Retrospective Analysis of Incidence, Risk Factors, and Survival Rates.

Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

Comparison of Hemorrhagic and Ischemic Stroke after Allogeneic Hematopoietic Stem Cell Transplantation

[Prognostic Analysis of Patients with Acute Leukemia and Central Nervous System Involvement Undergoing Allogeneic Hematopoietic Stem Cell Transplantation].

Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation for Patients with Hematologic Malignancies.

Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation]

Early and late complications of hematopoietic stem cell transplantation

[Therapeutic Effect of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimens on Hematological Malignancies].